Program
filgotinib
Also written as “Filgotinib”, “GLPG0634” and “GLPG0634 50 mg”.
Its studies are mostly in Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Arthritis, Psoriatic · Arthritis, Juvenile, led by 3 companies.
Drug pageGLPG0634: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lakefront Biotherapeutics NV | 230 open or running | phase 3since Sep 22, 2016 | Aug 10, 2010 | none ahead |
| Gilead Sciencesits history only | 160 open or running | phase 3since Aug 17, 2016 | Aug 17, 2016 | none ahead |
| Alfasigmaits history only | 74 open or running | phase 3since Sep 22, 2016 | Sep 22, 2016 | Jun 2027phase 3 · NCT07554495 |
Also a collaborator on its studies: Ono Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Lakefront Biotherapeutics NV only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Aug 10, 2010.
- Jun 26, 2013Phase 2 study in Arthritis, RheumatoidNCT01888874 · 599 enrolled · United States, Argentina, Australia and more
- Jul 4, 2013Phase 2 study in Arthritis, RheumatoidNCT01894516 · 287 enrolled · United States, Argentina, Australia and more
- Aug 2, 2013Phase 1 study in HealthyNCT01915667 · 12 enrolled · Belgium
- Jan 27, 2014Phase 2 study in Crohn DiseaseNCT02048618 · 175 enrolled · Belgium, Czech Republic, France and more
- Feb 14, 2014Phase 2 study in Arthritis, RheumatoidNCT02065700 · 739 enrolled · United States, Argentina, Australia and more
- Mar 9, 2014Phase 1 study in Renal InsufficiencyNCT02084199 · 24 enrolled · Germany
- Jun 11, 2014Phase 1 study in HealthyNCT02162355 · 36 enrolled · United Kingdom
- Sep 22, 20162 phase 3 studies in Crohn DiseaseNCT02914600, NCT02914561
- Mar 30, 20172 phase 2 studiesNCT03117270, NCT03101670
- Jun 26, 2017Phase 2 study in Inflammatory Bowel DiseasesNCT03201445 · 139 enrolled · United States, Australia, Austria and more
- Oct 20, 2017Phase 2 study in Arthritis, PsoriaticNCT03320876 · 122 enrolled · Belgium, Bulgaria, Czechia and more
- Apr 19, 2019Phase 2 study in Arthritis, RheumatoidNCT03926195 · 109 enrolled · Bulgaria, Czechia, Estonia and more
- Jul 26, 2022Phase 3 study in Colitis, UlcerativeNCT05479058 · 22 enrolled · United States, Belgium, Czechia and more
- Sep 11, 2023Phase 1 study in BioavailabilityNCT06043739 · 12 enrolled · Canada
TargetBeta
“An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
All 23 Lakefront Biotherapeutics NV leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06043739Bioavailability · Canada | 1 | Completed | Oct 27, 2023 | 12 |
| NCT05479058Colitis, Ulcerative · United States, Belgium, Czechia and more | 3 | Terminated | Oct 9, 2023 | 22 |
| NCT03926195Arthritis, Rheumatoid · Bulgaria, Czechia, Estonia and more | 2 | Completed | Aug 14, 2020 | 109 |
| NCT03320876Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more | 2 | Terminated | Jun 30, 2021 | 122 |
| NCT03201445Inflammatory Bowel Diseases · United States, Australia, Austria and more | 2 | Terminated | Nov 20, 2020 | 139 |
| NCT03117270Spondylitis, Ankylosing · Belgium, Bulgaria, Czechia and more | 2 | Completed | Jul 2, 2018 | 116 |
| NCT03101670Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more | 2 | Completed | Mar 12, 2018 | 131 |
| NCT02914600Crohn Disease · United States, Argentina, Australia and more | 3 | Terminated | Aug 1, 2023 | 1,188 |
| NCT02914561Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | Nov 11, 2022 | 1,372 |
| NCT02162355Healthy · United Kingdom | 1 | Completed | Sep 2014 | 36 |
| NCT02084199Renal Insufficiency · Germany | 1 | Completed | Jul 2014 | 24 |
| NCT02065700Arthritis, Rheumatoid · United States, Argentina, Australia and more | 2 | Completed | Jan 19, 2023 | 739 |
| NCT02048618Crohn Disease · Belgium, Czech Republic, France and more | 2 | Completed | Nov 2015 | 175 |
| NCT01915667Healthy · Belgium | 1 | Completed | Sep 2013 | 12 |
| NCT01894516Arthritis, Rheumatoid · United States, Argentina, Australia and more | 2 | Completed | Mar 5, 2015 | 287 |
| NCT01888874Arthritis, Rheumatoid · United States, Argentina, Australia and more | 2 | Completed | Feb 18, 2015 | 599 |
| NCT01820806Healthy · United Kingdom | 1 | Completed | Apr 2013 | 6 |
| NCT01798979Healthy · United States | 1 | Completed | Apr 2013 | 20 |
| NCT01668641Arthritis, Rheumatoid · Hungary, Moldova, Republic of, Russian Federation and more | 2 | Completed | Sep 2012 | 91 |
| NCT01665924Healthy · Belgium | 1 | Completed | Sep 2012 | 36 |
| NCT01419990Healthy · Belgium | 1 | Completed | Oct 2011 | 16 |
| NCT01384422Arthritis, Rheumatoid · Moldova, Republic of | 2 | Completed | Nov 2011 | 36 |
| NCT01179581Healthy · Belgium | 1 | Completed | Mar 2011 | 48 |
How it is read
Names in the registry
- “Filgotinib”, 32 entries
- “GLPG0634”, 11 entries
- “filgotinib”, 3 entries
- “GLPG0634 50 mg”, 1 entry
- “GLPG0634 100 mg”, 1 entry
Codes read as this program: GLPG0634.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 12 studies
- Crohn Disease, 5 studies
- Colitis, Ulcerative, 4 studies
- Arthritis, Psoriatic, 4 studies
- Arthritis, Juvenile, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.